Contact us

News

At Cell-Easy, we provide end-to-end GMP manufacturing services for advanced therapy medicinal products (ATMPs), with a strong focus on compliance, scalability, and reliability.

We help biotech and pharma companies bring innovative cell therapies from the lab to the clinic by combining high-quality starting material sourcing, robust process development, and clinical-grade GMP production that meets international standards (MHRA, ANSM, EMA, FDA readiness).

Whether you need early clinical batches or large-scale production, our tailored solutions optimize your process, minimize risks, and accelerate time-to-clinic.

Let’s talk about your project

  • Cell-Easy Appoints CDMO Expert Dr. Ribault to Its Board

    Cell-Easy Appoints CDMO Expert Dr. Ribault to Its Board Cell-Easy is a leading contract development and manufacturing organization (CDMO) with a strong foothold in Good Manufacturing Practice (GMP) manufacturing services for immune cells (T, NK cells) and adult stem cells (MSCs, iPSCs). Since 2020, the company keeps expanding into genetically modified cells such as CAR-T…

    Learn more: Cell-Easy Appoints CDMO Expert Dr. Ribault to Its Board

  • EMERCell & Cell-Easy sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001

    EMERCell & Cell-Easy sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001 Emercell has selected Cell-Easy as a long-term CDMO partner for the scale-up and manufacturing operations of its allogeneic NK cell-based product, with the objective to enter clinical phase in 2023. Emercell has signed a strategic agreement with Cell-Easy specialized in the…

    Learn more: EMERCell & Cell-Easy sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001

  • Cell-Easy Launches OPTI-STEM for Cell Therapy Access

    Cell-Easy Launches OPTI-STEM for Cell Therapy Access The OPTI-STEM consortium led by CDMO Cell-Easy receives €7M from the French government and Bpifrance and €800,000 from the Occitanie Region to democratize access to cell therapy in France and Europe The OPTI-STEM project aims to optimize the production of MSCs in order to democratize access to them…

    Learn more: Cell-Easy Launches OPTI-STEM for Cell Therapy Access